Metabolic changes and satisfaction associated with gender-affirming hormone therapy in transgender women

Hoyos Emilia Gomez; Asensio Lucia Estevez; Garcia Esther Delgado; Alonso Marta Mesonero; Bartolome Albistegui Maria Jose; Collantes Ruth Gonzalez; Maniega Rubio Maria Antonia; Fernandez Carmen Rodriguez; Marcos Ana Casas; Luis Daniel De

doi:10.1530/endoabs.110.EP931

EP931

Prev Next

Section Contents Cite

Endocrine Abstracts (2025) 110 EP931 | DOI: 10.1530/endoabs.110.EP931

ECEESPE2025 ePoster Presentations Metabolism, Nutrition and Obesity (164 abstracts)

Metabolic changes and satisfaction associated with gender-affirming hormone therapy in transgender women

Emilia Gomez Hoyos ¹ , Lucia Estevez Asensio ¹ , Esther Delgado Garcia ¹ , Marta Mesonero Alonso ¹ , Maria Jose Bartolome Albistegui ¹ , Ruth Gonzalez Collantes ¹ , Maria Antonia Maniega Rubio ¹ , Carmen Rodriguez Fernandez ¹ , Ana Casas Marcos ¹ & Daniel De Luis ¹

Author affiliations

¹Hospital Clinico Universitario de Valladolid, Valladolid, Spain

JOINT806

Introduction: Gender affirming hormone therapy (GAHT) in transgender women favors their feminization. Aims: To determine its metabolic impact and the satisfaction perceived by the subject (CRES-4 questionnaire).

Material and Methods: Prospective study in transgender women with GAHT (> 2 years), attended at the Transgender Medicine Unit of the Hospital Clinico of Valladolid from January 2014 to January 2023. Recording of clinical, analytical and CRES-4 questionnaire data after giving their consent. Statistical analysis of the data by the SPSS-V17 program.

Results: 36 transgender females aged 31 [23-42] years and onset of GAHT at 21 [17-30] years with oral estradiol 21 (58%) and transdermal estradiol 15 (42%). Besides 27 (75%) with cyproterone acetate and 9 (25%) with spironolactone. The initial BMI was 22 [20-25] kg/m², Total Cholesterol 160 [133-185], LDL 78 [69-129], HDL 54 [69-129], TG 76 [60-107] mg/dl. At 2 years with GAHT, BMI was 23[20-27] kg/m² (p 0.0939, the increase was 0.12 [-0.69 to 0.79] with oral estradiol and the 0.92 [-0.34 to 1.45] with transdermal estradiol (p 0.250). Total Cholesterol was 164 [140-188] (p 0.610), LDL 87 [63-127] (p 0.184), HDL 51 [40-72] (p 0.245) and Triglycerides was 72 [55-96] mg/dl (p 0.215). In trans women with oral estradiol the change of HDL was 12 [3-19] compared to - 3.5 [-11 to 14.25] mg/dl with transdermal estradiol (p 0.002). Subjects were satisfied with GAHT, with 250 [232-271] points on CRES-4. In women with oral estradiol was 250 [235-275] and transdermal estradiol 262 [230-277] (p 0.085).

Conclusion: Feminization hormone therapy induces a non-significant increase in BMI without deterioration of the lipid profile, with a significant increase in HDL cholesterol, mainly in women with oral estradiol. Although the satisfaction associated with hormonal therapy appears to be greater in women with transdermal estradiol.